Publications
Complete publication list (Pubmed search) :
>> Link
Representative publications :
van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, Olive D, Boon T, Coulie PG. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998;102:1376-9.
van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, André M, Ravoet C, Doyen C, Spagnoli GC, Bakkus M, Thielemans K, Boon T. Genes encoding tumor-specific antigens are expressed in human myeloma cells.Blood 1999;94:1156-64.
Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Liénard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jäger E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-30.
Chambost H, van Baren N, Brasseur F, Godelaine D, Xerri L, Landi SJ, Theate I, Plumas J, Spagnoli GC, Michel G, Coulie PG, Olive D. Expression of gene MAGE-A4 in Reed-Sternberg cells. Blood 2000;95:3530-3.
Boon T, Coulie PG, van der Bruggen P, van Baren N. Immunology of the cancer cell: T lymphocyte responses. In: Clinical Oncology, 2nd Edition. Eds: M. D. Abeloff, J.O. Armitage, A.S. Lichter, J.E. Niederhuber. Churchill Livingstone, New York, 2000.
Marchand M, Brichard V, van Baren N, Coulie PG. Biological and clinical developments in melanoma vaccines. Expert Opin Biol Ther 2001;1:497-510.
Machiels JP, van Baren N, Marchand M. Peptide-based Cancer Vaccines. Semin Oncol 2002;29:494-502.
Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Hakansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003;39:70-7.
Vialle-Castellano A, Laduron S, De Plaen E, Jost E, Dupont S, Ameye G, Michaux L, Coulie P, Olive D, Boon T, van Baren N. A gene expressed exclusively in acute B lymphoblastic leukemias. Genomics 2004;83:85-94
Kruit W, van Ojik H, Brichard V, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril M-F, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont A, Marchand M. Phase I/II study of subcutaneous and intradermal immu- nization with a recombinant MAGE-3 protein in patients with detectable non-visceral metastatic melanoma. Int J Cancer 2005;117:596-604.
van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T. Tumoral and immunological response following baccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005;23:9008-21.
Baurain JF, Van der Bruggen P, Van den Eynde BJ, Coulie PG, Van Baren N. General principles and first clinical trials of therapeutic vaccines against cancer. Bull Cancer 2008;95:327-35 (in French)
